Creek Drive Management Group LLC Invests $723,000 in Palisade Bio, Inc. $PALI

Creek Drive Management Group LLC purchased a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 307,500 shares of the company’s stock, valued at approximately $723,000.

Several other institutional investors have also recently made changes to their positions in the company. XTX Topco Ltd lifted its holdings in Palisade Bio by 53.8% in the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after acquiring an additional 7,584 shares during the last quarter. Cetera Investment Advisers acquired a new stake in Palisade Bio during the fourth quarter worth $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in Palisade Bio during the fourth quarter worth $26,000. Virtu Financial LLC purchased a new stake in Palisade Bio in the fourth quarter valued at $28,000. Finally, Atom Investors LP purchased a new stake in Palisade Bio in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Stock Performance

Shares of PALI stock opened at $1.87 on Friday. The company has a 50 day moving average price of $1.97 and a 200 day moving average price of $1.90. The stock has a market capitalization of $324.59 million, a P/E ratio of -1.85 and a beta of 1.52. Palisade Bio, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.85.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, research analysts forecast that Palisade Bio, Inc. will post -0.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PALI has been the topic of several recent analyst reports. HC Wainwright assumed coverage on Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock. Wolfe Research started coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Stifel Nicolaus began coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.20.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.